巨核白血病细胞系(HI—Meg)对抗癌药物敏感性的测定及其意义

ASSAY OF ANTI—TUMOUR DRUG SENSITIVITY OF HUMAN MEGAkARYOBLASTIG LEUkEMIC CELL LINE (HI—MEG) AND SIGNIFICANCP

摘要: 应用~3H—TdR掺入、死活细胞计数和集落形成试验三种体外药物检测方法,测定了人巨核白血病细胞系(HI—Meg)对6种临床抗癌药物的敏感性,并用人早幼粒白血病细胞系(HL—60)作比较。结果表明6种药物对两株细胞均有较好的剂量效应曲线和较高的敏感性。HI—Meg的建立为抗癌药物筛选提供了一个新的模型,并可用于寻找和筛选有效的抗巨核细胞白血病的药物。

Abstract: The sensitivity of human megakaryoblastic leukemic cell line(HI-Meg)and human promylocytic leukemic cell line (HL-60) to six clinical anti-tumour drugs was studied with ~3H-TdR incorporation, colony forming assay and alive cell account. These cell tines appeared proper dose respons curves and high sensitivity to six drugs HI-Meg cell line may be a new cellular model for screening for anti-tumour drugs, especially for effective drugs against megakaryoblastic leukemie.